These emerging medications , Semaglutide , represent a groundbreaking advancement in managing type 2 diabetes and possibly other disorders. These drugs are grouped as GLP-1 receptor agonists , indicating they to mimic the endogenous GLP-1 hormone , stimulating glucose secretion and reducing appet